[go: up one dir, main page]

MX2024011519A - Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario. - Google Patents

Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.

Info

Publication number
MX2024011519A
MX2024011519A MX2024011519A MX2024011519A MX2024011519A MX 2024011519 A MX2024011519 A MX 2024011519A MX 2024011519 A MX2024011519 A MX 2024011519A MX 2024011519 A MX2024011519 A MX 2024011519A MX 2024011519 A MX2024011519 A MX 2024011519A
Authority
MX
Mexico
Prior art keywords
sub
antibody
sup
conjugates
targeting
Prior art date
Application number
MX2024011519A
Other languages
English (en)
Inventor
Lianne Lelieveldt
Geel Remon Van
Berkel Sander Sebastiaan Van
Delft Floris Louis Van
Original Assignee
Synaffix Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaffix Bv filed Critical Synaffix Bv
Publication of MX2024011519A publication Critical patent/MX2024011519A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a conjugados de anticuerpos que son especialmente adecuados para dirigir células que expresan CEA, en particular células tumorales. Los conjugados de anticuerpos de acuerdo con la invención tienen la estructura (1):AB-[(L6)b-{Z-L-D}x]y (1); en la presente, AB es un anticuerpo capaz de dirigirse a tumores que expresan CEA; L es un ligador que une Z a D; Z es un grupo de conexión; L6 es -GlcNAc(Fuc)w-(G)j-S-(L7)w-, en donde G es un monosacárido, j es un número entero en el rango de 0 - 10, S es un azúcar o un derivado del azúcar, GlcNAc es N-acetilglucosamina y Fuc es fucosa, w es 0 o 1, w' es 0, 1 o 2 y L7 es -N(H)C(O)CH2-, -N(H)C(O)CF2- o -CH2-; D se selecciona del grupo que consiste en antraciclinas, camptotecinas, tubulisinas, enediinas, amanitinas, duocarmicinas, maitansinoides, auristatinas, eribulinas, inhibidores de BCL-XL, hemiasterlinas, inhibidores de KSP, agonistas de TLR, dímeros de indolinobenzodiazepina o dímeros de pirrolobenzodiazepina (PBD), y análogos o profármacos de estos; b es 0 o 1; x es 1 o 2; e y es 1, 2, 3 o 4. La invención se refiere además a un método para preparar los conjugados de anticuerpos de la estructura (1) y a la aplicación de los conjugados de anticuerpos de la estructura (1).
MX2024011519A 2022-03-23 2023-03-23 Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario. MX2024011519A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22163928 2022-03-23
PCT/EP2023/057565 WO2023180489A1 (en) 2022-03-23 2023-03-23 Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen

Publications (1)

Publication Number Publication Date
MX2024011519A true MX2024011519A (es) 2024-09-24

Family

ID=80930396

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011519A MX2024011519A (es) 2022-03-23 2023-03-23 Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.

Country Status (10)

Country Link
US (1) US20250082770A1 (es)
EP (1) EP4496595A1 (es)
JP (1) JP2025510678A (es)
KR (1) KR20250024741A (es)
CN (1) CN119233830A (es)
AU (1) AU2023237620A1 (es)
CA (1) CA3254964A1 (es)
IL (1) IL315205A (es)
MX (1) MX2024011519A (es)
WO (1) WO2023180489A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3876998A1 (en) 2018-11-05 2021-09-15 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
MX2024011518A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el tratamiento de tumores que expresan ptk7.
WO2025005240A1 (ja) * 2023-06-30 2025-01-02 第一三共株式会社 活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法
WO2025238253A1 (en) * 2024-05-16 2025-11-20 Synaffix B.V. Antibody-oligonucleotide conjugates

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
GB9317423D0 (en) 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9621295D0 (en) 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
CA2501616C (en) 2002-10-08 2015-05-12 Immunomedics, Inc. Antibody therapy
US7273608B2 (en) 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
US8394926B2 (en) 2005-12-21 2013-03-12 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA
WO2008029281A2 (en) 2006-02-10 2008-03-13 Invitrogen Corporation Labeling and detection of post translationally modified proteins
WO2009102820A2 (en) 2008-02-11 2009-08-20 Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services Modified sugar substrates and methods of use
CA2770174A1 (en) 2009-08-31 2011-03-03 Roche Glycart Ag Affinity-matured humanized anti cea monoclonal antibodies
PL2621955T3 (pl) 2010-10-01 2018-07-31 National Research Council Of Canada Przeciwciała anty-CEACAM6 i ich zastosowania
PT2681244T (pt) 2011-03-02 2018-01-24 Roche Glycart Ag Anticorpos do cea
SMT201800096T1 (it) 2012-10-23 2018-05-02 Synaffix Bv Anticorpo modificato, coniugato di anticorpo e processo per la preparazione degli stessi
TWI664192B (zh) 2012-11-20 2019-07-01 法商賽諾菲公司 抗ｃｅａｃａｍ５抗體及其用途
HK1216176A1 (zh) * 2012-12-21 2016-10-21 Medlmmune Limited 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
WO2015069430A2 (en) 2013-11-05 2015-05-14 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
EP3177633B1 (en) 2014-08-04 2022-07-20 SynAffix B.V. Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
WO2016053107A1 (en) 2014-10-03 2016-04-07 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
PE20171790A1 (es) 2015-03-23 2017-12-28 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos
PL3134520T3 (pl) 2015-04-23 2018-06-29 Synaffix B.V. Sposób modyfikacji glikoproteiny z zastosowaniem glikozylotransferazy, która jest lub pochodzi od β-(1,4)-N-acetylogalaktozaminylotransferazy
WO2017137458A1 (en) * 2016-02-08 2017-08-17 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
WO2017137456A1 (en) * 2016-02-08 2017-08-17 Synaffix B.V. Bioconjugates containing sulfamide linkers for use in treatment
WO2017137457A1 (en) * 2016-02-08 2017-08-17 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
CN109475567A (zh) 2016-06-09 2019-03-15 布兰克生物股份有限公司 基于硅烷醇的治疗有效载荷
WO2019110725A1 (en) 2017-12-06 2019-06-13 Synaffix B.V. Enediyne conjugates
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
KR102679892B1 (ko) 2019-03-29 2024-07-02 메디뮨 리미티드 화합물 및 이의 접합체
HRP20231619T1 (hr) 2019-04-26 2024-04-26 Immunogen, Inc. Derivati kamptotecina
HUE067160T2 (hu) 2019-09-18 2024-10-28 Lamkap Bio Alpha AG Bispecifikus antitestek CEACAM5 és CD3 ellen
KR20230021018A (ko) 2020-06-05 2023-02-13 재단법인 생물기술개발중심 항-메조텔린 항체를 함유하는 항체-약물 컨쥬게이트 및 이의 용도
NL2026947B1 (en) 2020-11-20 2022-07-01 Synaffix Bv Tyrosine-based antibody conjugates
CN113816969B (zh) 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
WO2023000131A1 (zh) 2021-07-19 2023-01-26 烟台迈百瑞国际生物医药股份有限公司 一种负载双毒素的抗体药物偶联物及其应用

Also Published As

Publication number Publication date
JP2025510678A (ja) 2025-04-15
CN119233830A (zh) 2024-12-31
US20250082770A1 (en) 2025-03-13
AU2023237620A1 (en) 2024-08-29
CA3254964A1 (en) 2023-09-28
KR20250024741A (ko) 2025-02-19
IL315205A (en) 2024-10-01
WO2023180489A1 (en) 2023-09-28
EP4496595A1 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
MX2024011519A (es) Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.
MX2024011518A (es) Conjugados de anticuerpos para el tratamiento de tumores que expresan ptk7.
Damle Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
EP3876998A1 (en) Antibody-conjugates for targeting of tumours expressing trop-2
TW202015740A (zh) 喜樹鹼結合物
Kerr et al. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide
CN109069664A (zh) 抗cd74抗体偶联物，包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法
US20210138080A1 (en) Conjugates
WO2020236817A8 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2019215510A8 (en) Compositions and methods related to anti-cd19 antibody drug conjugates
EP4450521A1 (en) Antibody-drug conjugate targeting claudin18.2
CN119367549A (zh) 亲水性接头及其共轭物
IE882379L (en) Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
WO2005077090A2 (en) Improved methods of producing antibody conjugates
US20210402002A1 (en) Conjugate
MX2024011520A (es) Conjugados de anticuerpos para el direccionamento contra tumores que expresan trop-2
US20230038373A1 (en) Stabile conjugate
US12403185B2 (en) Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
JPWO2023280092A5 (es)
WO2024182569A3 (en) Anti-psma antibodies, conjugates, and methods of use
Fodstad et al. New indirect approach to the therapeutic use of immunotoxins
Avila et al. Construction of an immunotoxin by linking a monoclonal antibody against the human epidermal growth factor receptor and a hemolytic toxin
HIRATA et al. Monoclonal antibody to proteoglycan derived from Grifola frondosa (Maitake)
CN119345386B (zh) 靶向Claudin18.2的抗体药物耦联物及其用途
Yang1&3 et al. Reducing the Complexity of Fc Glycan Enables the Construction of Antibody Conjugates with Unexpected High Efficiency and Payload Capacity via Glycoengineering.